Van Berkom & Associates’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $86.4M | Buy |
501,152
+50,462
| +11% | +$9.36M | 2.81% | 7 |
|
|
2025
Q4 | $89.9M | Sell |
450,690
-46,221
| -9% | -$8.38M | 2.59% | 11 |
|
|
2025
Q3 | $77.7M | Buy |
496,911
+9,962
| +2% | +$1.58M | 2.25% | 18 |
|
|
2025
Q2 | $73.9M | Buy |
486,949
+39,863
| +9% | +$5.32M | 2.2% | 27 |
|
|
2025
Q1 | $67.3M | Buy |
447,086
+59,088
| +15% | +$9.91M | 2.16% | 25 |
|
|
2024
Q4 | $71.6M | Sell |
387,998
-1,836
| -0.5% | -$354K | 2.13% | 26 |
|
|
2024
Q3 | $76.8M | Buy |
389,834
+71,606
| +23% | +$14.9M | 2.11% | 29 |
|
|
2024
Q2 | $65.7M | Buy |
318,228
+6,762
| +2% | +$1.53M | 1.96% | 31 |
|
|
2024
Q1 | $84.4M | Sell |
311,466
-6,947
| -2% | -$1.66M | 2.4% | 16 |
|
|
2023
Q4 | $75.3M | Buy |
318,413
+96,215
| +43% | +$18.9M | 2.19% | 27 |
|
|
2023
Q3 | $43.5M | Buy |
222,198
+33,570
| +18% | +$6.89M | 1.42% | 39 |
|
|
2023
Q2 | $39.7M | Sell |
188,628
-2,377
| -1% | -$473K | 1.44% | 40 |
|
|
2023
Q1 | $38.5M | Buy |
191,005
+10,955
| +6% | +$2.48M | 1.43% | 41 |
|
|
2022
Q4 | $39.2M | Buy |
180,050
+9
| +0% | +$1.97K | 1.68% | 36 |
|
|
2022
Q3 | $35.4M | Sell |
180,041
-18,905
| -10% | -$4.08M | 1.68% | 34 |
|
|
2022
Q2 | $42.6M | Sell |
198,946
-2,421
| -1% | -$592K | 1.78% | 33 |
|
|
2022
Q1 | $57.2M | Sell |
201,367
-20,553
| -9% | -$6.34M | 2.05% | 26 |
|
|
2021
Q4 | $83.6M | Sell |
221,920
-5,765
| -3% | -$2.24M | 2.47% | 14 |
|
|
2021
Q3 | $94M | Sell |
227,685
-114,641
| -33% | -$47.6M | 2.85% | 7 |
|
|
2021
Q2 | $127M | Sell |
342,326
-164,338
| -32% | -$54.9M | 3.48% | 2 |
|
|
2021
Q1 | $147M | Sell |
506,664
-33,463
| -6% | -$9.3M | 3.21% | 4 |
|
|
2020
Q4 | $135M | Sell |
540,127
-3,637
| -0.7% | -$866K | 3.09% | 7 |
|
|
2020
Q3 | $123M | Sell |
543,764
-120,091
| -18% | -$24.9M | 3.57% | 3 |
|
|
2020
Q2 | $116M | Sell |
663,855
-39,945
| -6% | -$6.38M | 3.39% | 5 |
|
|
2020
Q1 | $88.8M | Buy |
703,800
+119,919
| +21% | +$18M | 3.18% | 7 |
|
|
2019
Q4 | $89.2M | Buy |
583,881
+939
| +0.2% | +$130K | 2.41% | 17 |
|
|
2019
Q3 | $77.2K | Buy |
582,942
+8,665
| +2% | +$1.16M | 1.89% | 21 |
|
|
2019
Q2 | $81.5M | Sell |
574,277
-1,495
| -0.3% | -$203K | 2.36% | 14 |
|
|
2019
Q1 | $83.6M | Sell |
575,772
-8,279
| -1% | -$1.09M | 2.65% | 9 |
|
|
2018
Q4 | $66.1M | Sell |
584,051
-20,204
| -3% | -$2.53M | 2.33% | 14 |
|
|
2018
Q3 | $81.3M | Sell |
604,255
-13,136
| -2% | -$1.62M | 2.31% | 14 |
|
|
2018
Q2 | $69.3M | Buy |
617,391
+4,250
| +0.7% | +$459K | 2.02% | 25 |
|
|
2018
Q1 | $65.4M | Buy |
613,141
+23,504
| +4% | +$2.53M | 1.99% | 29 |
|
|
2017
Q4 | $64.5M | Sell |
589,637
-62,216
| -10% | -$6.77M | 2.1% | 19 |
|
|
2017
Q3 | $70.4M | Sell |
651,853
-116,060
| -15% | -$11.9M | 2.53% | 11 |
|
|
2017
Q2 | $77.7M | Buy |
767,913
+2,970
| +0.4% | +$273K | 2.81% | 5 |
|
|
2017
Q1 | $68.8M | Sell |
764,943
-52,550
| -6% | -$4.46M | 2.58% | 10 |
|
|
2016
Q4 | $62.3M | Buy |
817,493
+121,600
| +17% | +$9.24M | 2.5% | 10 |
|
|
2016
Q3 | $58M | Buy |
695,893
+33,580
| +5% | +$2.81M | 2.46% | 10 |
|
|
2016
Q2 | $54.6M | Sell |
662,313
-21,585
| -3% | -$1.78M | 2.5% | 11 |
|
|
2016
Q1 | $51.9M | Sell |
683,898
-35,436
| -5% | -$2.62M | 2.36% | 14 |
|
|
2015
Q4 | $57.8M | Buy |
719,334
+34,470
| +5% | +$2.49M | 2.86% | 6 |
|
|
2015
Q3 | $43.5M | Buy |
684,864
+107,629
| +19% | +$7.73M | 2.18% | 17 |
|
|
2015
Q2 | $40.6M | Sell |
577,235
-13,270
| -2% | -$982K | 1.92% | 33 |
|
|
2015
Q1 | $46.8M | Sell |
590,505
-150,670
| -20% | -$11.1M | 2.13% | 24 |
|
|
2014
Q4 | $47.2M | Sell |
741,175
-65,725
| -8% | -$4.12M | 2.28% | 16 |
|
|
2014
Q3 | $48.2M | Buy |
806,900
+92,131
| +13% | +$5.27M | 2.41% | 14 |
|
|
2014
Q2 | $38.3M | Buy |
714,769
+75,688
| +12% | +$4.15M | 2.09% | 26 |
|
|
2014
Q1 | $38.6M | Sell |
639,081
-174,461
| -21% | -$10.2M | 2.17% | 22 |
|
|
2013
Q4 | $43.1M | Buy |
813,542
+85,133
| +12% | +$4.28M | 2.41% | 15 |
|
|
2013
Q3 | $33.7M | Sell |
728,409
-54,922
| -7% | -$2.52M | 2.17% | 23 |
|
|
2013
Q2 | $32.1M | Buy |
+783,331
| New | +$33.6M | 2.41% | 17 |
|
Other funds holding CRL
VCM
VPM
Van Berkom & Associates's CRL Position: Q1 2026 in Review
Van Berkom & Associates increased its Charles River Laboratories (CRL) stake by 11% in Q1 2026, buying an estimated $9.36M and bringing the position to 501,152 shares worth $86.4M. The position accounts for 2.81% of the portfolio, ranked #7.
Van Berkom & Associates first reported a position in CRL in Q2 2013 and has held it in 52 quarters since. The position peaked at $147M in Q1 2021. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Van Berkom & Associates held 501,152 shares of Charles River Laboratories worth $86.4M as of Q1 2026.
- Van Berkom & Associates bought 50,462 Charles River Laboratories shares in Q1 2026, an estimated $9.36M.
- Charles River Laboratories made up 2.81% of Van Berkom & Associates's portfolio in Q1 2026, its #7 holding.
- Van Berkom & Associates first reported a position in Charles River Laboratories in Q2 2013 and has held it in 52 quarters since.
- Van Berkom & Associates's Charles River Laboratories position peaked at $147M in Q1 2021.
- 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Van Berkom & Associates's 13F filing for Q1 2026, filed 7 May 2026.